🔎 Trials Near Me

Home › Kanser sa Dugo › California › Baldwin Park

Pag-aaral pangklinika para sa Kanser sa Dugo sa Baldwin Park, CA

Isang pag-aaral para sa Kanser sa Dugo ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Baldwin Park. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

Nagre-recruitPhase 3
  • Quetzal Site 1, Duarte · 4 mi ang layo
Edad 18 hanggang 71 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07504458

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Nagre-recruitPhase 1
  • City of Hope Medical Center, Duarte · 4 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07195916

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Nagre-recruitPhase 2
  • City of Hope Comprehensive Cancer Center, Duarte · 4 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT04996875

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo
  • City of Hope, Duarte · 4 mi ang layo
Edad 12 hanggang 120 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT05436418

M-2018-334 in Hematological Malignancies

Nagre-recruit
  • City of Hope, Duarte · 4 mi ang layo
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06225050

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Nagre-recruitPhase 1/2
  • City of Hope National Medical Center, Duarte · 4 mi ang layo
Edad 12 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT04588922

Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy

Nagre-recruitPhase 3Malugod na tinatanggap ang malusog na boluntaryo
  • City of Hope Medical Center, Duarte · 4 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07186192

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

Nagre-recruitPhase 1
  • City Of Hope, Duarte · 4 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT06823167

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

Nagre-recruitPhase 2
  • City of Hope National Medical Center, Duarte · 4 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT06665100

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Nagre-recruitObservasyonal na pag-aaral
  • City of Hope, Duarte · 4 mi ang layo
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545

IVIG for Infection Prevention After CAR-T-Cell Therapy

Nagre-recruitPhase 2
  • City of Hope Cancer Center, Duarte · 4 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT05952804

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Nagre-recruitPhase 1/2
  • City of Hope, Duarte · 4 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 16, 2026 · NCT03328078

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Nagre-recruitPhase 1
  • City of Hope, Duarte · 4 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 15, 2025 · NCT06462365

Pag-aaral para sa Kanser sa Dugo sa ibang lungsod

Iba pang pag-aaral sa Baldwin Park

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.